Published in final edited form as:

Curr Top Microbiol Immunol. 2017 ; 407: 31–63. doi:10.1007/82_2017_33.

Virus-Host Gene Interactions Define HIV-1 Disease Progression

Daniela C. Monaco¹, Zachary Ende¹, and Eric Hunter^{1,2}

¹Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329

²Department of Pathology and Laboratory Medicine, Emory University, 954 Gatewood Road, Atlanta, GA 30329

Abstract

In this chapter, we will review recent research on the virology of HIV-1 transmission and the impact of the transmitted virus genotype on subsequent disease progression. In most instances of HIV-1 sexual transmission, a single genetic variant, or a very limited number of variants from the diverse viral quasi-species present in the transmitting partner establishes systemic infection. Transmission involves both stochastic and selective processes, such that in general a minority variant in the donor is transmitted. While there is clear evidence for selection, the biological properties that mediate transmission remain incompletely defined. Nevertheless, the genotype of the transmitted founder virus, which reflects prior exposure to and escape from host immune responses, clearly influences disease progression. Some escape mutations impact replicative capacity, while others effectively cloak the virus from the newly infected host's immune response by preventing recognition. It is the balance between the impact of escape mutations on viral fitness and susceptibility to the host immunogenetics that defines HIV-1 disease progression.

Keywords

HIV transmission; transmitted founder virus; HIV pathogenesis; replicative capacity; immune escape

Introduction

The current HIV/AIDS pandemic reflects a combination of sub-epidemics that vary in routes of transmission, prevalence and incidence rates, different at-risk populations, and viral subtypes. Overall in 2014, an estimated 36.7 million people were living with HIV-1, and 2.1 million new HIV-1 infections occurred globally (UNAIDS 2016). HIV-1, the causative agent of the AIDS pandemic and a member of the *lentivirus* genus of the family *Retroviridae*, continues to contribute to over 1 million deaths globally every year and has been coevolving in its only permissive host, humans, for many decades.

Dedication: This chapter is dedicated to Peter K. Vogt in honor of his 50 years as an Editor of Current Topics of Microbiology and Immunology, his continued contributions to science and 45 years of mentorship and friendship.

As with all retroviruses, HIV-1 integrates a copy of its genome into the chromosome of the host cell and establishes a chronic infection that is subject to immune control by the host; although, HIV-1 infects a subset of cells, CD4⁺ T cells, that play a key role in orchestrating the immune response. Nevertheless, HIV-1 induces robust humoral and cellular immune responses, the latter of which can limit virus replication to varying degrees (Walker and Yu 2013). Genome-wide association studies have indicated that while genes in the human leukocyte antigen (HLA) locus account for the bulk of host control over virus replication, HLA can only account for approximately one-quarter of the observed variation in setpoint viremia (Fellay et al. 2007; McLaren et al. 2015). In this review, we will discuss recent data that suggest both control of viral replication and disease progression are the result of complex and evolving interplay between the virus that initiates infection and the host immune response.

HIV-1 transmission

Heterosexual transmission of HIV-1 remains the predominant mode of transmission, particularly in sub-Saharan Africa, accounting for nearly 75% of new transmissions worldwide. In contrast, in developed countries of the Western Hemisphere, men who have sex with men (MSM) continue to represent a majority of those newly acquiring HIV-1. Transmission via direct blood-to-blood contact through intravenous drug use (IDU) or contaminated blood transfusions constitutes a small percentage (<10%) of infections in the U.S., but transmission among IDUs is a significant contributor in parts of Southeast Asia and Eastern Europe. The risk of sexually transmitted infection by HIV-1 is highly dependent on the route of transmission; exposure in MSM via the rectum has an estimated infection probability ranging from 1 in 20 to 300, whereas for infection via the male genital tract the risk ranges from 1 in 300 to 7000. Infection in the female genital tract carries a risk of approximately 1 in 200 to 2000 (Hladik and McElrath 2008). Frequencies of transmission vary based on a number of factors that include the stage of infection and the level of viremia in the transmitting partner, with the risk of infection from patients with acute and early infection being significantly higher than that from those with established infection (Brenner et al. 2007; Miller et al. 2010; Powers et al. 2008; Wawer et al. 2005). This likely reflects the high viral loads (VL) observed in acute infection (Pilcher et al. 2007), lack of neutralizing antibody which may otherwise inactivate a majority of circulating virions in established infection, and essentially clonal amplification of a virus capable of initiating productive infection (see below). Other factors that have been shown to modulate the efficiency of sexual transmission include sexually transmitted diseases, particularly those that result in genital inflammation and ulcers, which can elevate HIV-1 shedding into the genital tract and increase the risk of infection 21-fold (Galvin and Cohen 2004); pregnancy during which a greater than two-fold increase in HIV-1 transmission has been observed (Gray et al. 2005); and circumcision, which in a series of clinical trials was shown to decrease transmission to the male by 60% (Auvert et al. 2005; Bailey et al. 2007; Gray et al. 2007). Transmission may also be biased by the viral subtype present in the population (Kiwanuka et al. 2009; Kamali et al. 2015).

Current concepts of genital tract infection and systemic spread.

The non-human primate model of HIV-1 infection has proven to be a powerful tool for experimentally investigating the transmission event since it is not possible to study the earliest steps of sexual transmission in human subjects. It is well established that HIV-1 has evolved from a simian immunodeficiency virus (SIV_{cpz}) that naturally infects a species of chimpanzee, *Pan troglodytes troglodytes*, while HIV-2 is derived from another that naturally infects sooty mangabeys (*Cercocebus atys*; SIV_{smm}) (Hahn et al. 2000). While relatively benign in its natural host, SIV_{sm} can be adapted to replicate in and induce a rapid immunodeficiency disease in rhesus macaque monkeys similar to that induced by HIV-1 in humans (Paiardini et al. 2009; Klatt et al. 2012). Pathogenic variants isolated from rhesus macaques, referred to as SIV_{mac}, have been particularly informative in defining steps involved in transmission of and systemic infection by primate lentiviruses when used in intra-vaginal and intra-rectal challenge models (Hatzioannou and Evans 2012; Evans and Silvestri 2013). Studies using high doses of SIV_{mac251} led to a model whereby SIV interaction with the cervicovaginal mucosa induces an innate response, amplified by recruitment of macrophages and plasmacytoid dendritic cells, that signals activated T cells to migrate to the site of infection. This increased availability of CD4⁺ target cells allows amplification of infection from the initially infected cell, a partially activated mucosal CD4⁺ T cell, to a level where virus or virus-infected cells can exit the mucosal tissue and travel to distal sites. These include regional lymph nodes and the gut-associated lymphoid tissue (GALT), where the bulk of early viral replication and T cell depletion occurs. This model of a localized inflammatory response playing a role in facilitating transmission is supported by experiments demonstrating that vaginal infection could be inhibited by local application of glycerol monolaurate, an inhibitor of inflammation (Li et al. 2009). However, the need for local amplification of infection was recently questioned following a large study, where animals were infected intravaginally with a high dose of SIV_{mac251} and serially necropsied on days 0, 1, 3, 7, and 10. In this study, virus was occasionally detectable in tissues distal from the genital mucosa, such as the gastrointestinal tract, by day 1, and 89% (8 of 9) of animals had detectable levels of viral RNA in at least one distal tissue by day 3, suggesting that viral dissemination can occur rapidly (Barouch et al. 2016). However, the role of these early distal infections in the establishment of systemic infection remains unclear since plasma viremia was not detected until day 10 in a majority of the animals. It is also important to recognize that these high dose infections may not be directly comparable to human sexual transmission, where the inoculum of infectious virus is likely to be much lower.

Although a variety of potential initial targets of infection have been postulated, including resting CD4⁺ T cells, macrophages and dendritic cells, Hope and colleagues recently demonstrated that Th17-lineage CCR6⁺ CD4⁺ T cells are the predominant targets of SIV during vaginal transmission by using a high titer, single-round non-replicating SIV construct that expresses luciferase and m-Cherry, (Stieh et al. 2014; Stieh et al. 2016). This cell type plays a key role in maintaining the integrity of the gut mucosa and is rapidly depleted following both SIV and HIV-1 infection (Blaschitz and Raffatellu 2010; Dandekar et al. 2010; Cecchinato and Franchini 2010).

HIV-1 transmission is linked to a genetic bottleneck

The concept that transmission of HIV-1 involves a genetic bottleneck, in which one or a limited number of variants from the diverse population present in the transmitting partner establish productive infection in the uninfected partner, was first established in studies over two decades ago. By analyzing viral sequences from early time points in primary HIV-1 infection, as well as, in some cases, viral sequences from the donors of a small number of linked heterosexual, homosexual and mother-to-child transmissions, these studies demonstrated that the virus population in the newly infected individual was much less diverse than that in the transmitting partner or mother (Wolinsky et al. 1992; Wolfs et al. 1992; Zhu et al. 1993; Zhang et al. 1993). Wolfs et al. also observed that in the two heterosexual transmissions described, the transmitted virus appeared to be a minor variant in the blood of the transmitters.

The difficulty of obtaining samples at early time points after infection, and from donors of linked HIV-1 transmission pairs, hindered the investigation of transmitted viral characteristics for over a decade. At this time a more in-depth analysis was performed using samples from heterosexual transmissions in a previously established cohort of serodiscordant couples in Lusaka, Zambia (Derdeyn et al. 2004). Derdeyn et al. sequenced almost 300 cloned HIV-1 Subtype C Envelope gene amplicons derived from 8 heterosexual transmission pairs shortly after transmission, and performed genetic and phenotypic studies (Derdeyn et al. 2004). A strength of this study was that the donor and recipient pairs were confirmed to be epidemiologically linked (Trask et al. 2002). A strong genetic bottleneck was observed in each transmission pair, in that the *env* sequences derived from each linked recipient emanated from a single branch on their respective donor *env* sequence phylogenetic tree, arguing that a single transmitted founder (T/F) virus established infection in each case.

More definitive analyses have relied on the use of end-point dilution PCR (termed single genome amplification or SGA (Salazar-Gonzalez et al. 2008)) to amplify sequences from multiple single genomes present in plasma very early after primary infection of individuals followed by direct sequencing of the DNA amplicon. This approach, in contrast to bulk PCR followed by cloning, avoids sequencing errors introduced by the Taq polymerase, *in vitro* recombination induced by template switching during the PCR reaction, and non-proportional representation of sequences as a result of template resampling. Furthermore, it has been possible to define the number of T/F variants, and the nucleotide sequence of each variant, by applying a mathematical model of early virus evolution to the SGA sequences (Lee et al. 2009). This model assumes that, in the absence of immune selection, replicating genomes accumulate random mutations at a constant rate defined in large part by the error rate of the reverse transcriptase. Using this approach, Keele and colleagues showed that 78 out of 102 subjects with acute subtype B HIV-1 infection had evidence of systemic infection by a single virus, while the remaining 24 had been infected by approximately two to five viruses (Keele et al. 2008). Applying this same method to 20 subtype A and C heterosexual transmission pairs for whom multiple sequences from both partners were derived, Haaland et al. (Haaland et al. 2009) determined that a single T/F virus established infection in 90% of cases, while an analysis of 69 newly infected subtype C individuals from South Africa by Abrahams et

al. (Abrahams et al. 2009) showed that 78% involved single variant transmission. It is clear from such studies, that, in situations where multiple viruses initiate infection, the number of infecting variants does not follow a Poisson distribution, with a majority involving only two or three variants but occasionally more than five. This is inconsistent with each variant being transmitted independently with low probability (Abrahams et al. 2009). Most likely, in these cases, factors such as sexually transmitted infections and potentially, in young women, the use of hormonal contraceptives, lowered the barrier to transmission (Haaland et al. 2009; Sagar et al. 2004).

Modulation of the genetic bottleneck:

Inflammatory responses to both the existing microbiome as well as to sexually transmitted infections clearly increase the frequency of HIV-1 transmission. Recent studies of young women in a South African cohort have shown that in those where the microbiome is deficient in *Lactobacillus* species, and yet diverse with *Prevotella* and *Gardnerella* species, there are increased genital pro-inflammatory cytokine concentrations (Anahtar et al. 2015). This ecologically diverse, *Lactobacillus* deficient microbiome was also associated with a higher risk of HIV-1 acquisition (Gosmann et al. 2017). Moreover, sexually transmitted infections (STIs), including herpes simplex type 2, which induce inflammation and ulcers in an uninfected partner, as well as similar infections in the transmitting partner, are known to increase the risk of transmission (Galvin and Cohen 2004).

Although not necessarily impacting the multiplicity of infection, viral load in the transmitting partner has been shown to modulate the likelihood of transmission. Studies in HIV-1 discordant couples have shown that partners with VL less than 10,000 copies/ml only rarely transmitted to their partners, while those with VL greater than 100,000 copies/ml transmitted much more frequently, with on average a 2.5-fold increase in risk with each $\log_{10}$ increase in VL (Quinn et al. 2000; Fideli et al. 2001). In Zambian discordant couples this increased risk was most evident in female to male (FTM) transmissions (Fideli et al. 2001). This increased risk may reflect higher VL in the genital tract of the transmitting partner (Pilcher et al. 2007) and a greater chance of virus reaching the genital mucosa. This is also consistent with NHP studies where both the frequency of infection and the number of transmitted variants increased with the dose of the inoculum (Liu et al. 2010). Moreover, in the macaque model, SIV in the plasma from animals in the acute stage of infection, where potentially neutralizing antibodies are absent, has a specific infectivity almost 100 times greater than that of virus in the plasma from chronically infected animals (Ma et al. 2009).

As highlighted by Joseph et al. 2015 and shown in Figure 1, virus transmission can fail at multiple steps following inoculation onto a mucosal surface (Joseph et al. 2015). Thus, STIs could abrogate the barrier imposed by an intact mucosa by inducing breaks in the epithelial lining thereby allowing more viral variants to initiate infection in the mucosal tissue; alternatively, inflammation induced by genital infections could increase the availability of activated CD4⁺ cells required to establish a spreading infection, in this way allowing infections that would have failed due to lack of target cells to expand. It is still not defined, under conditions of low multiplicity of infection, where the probability of infection is less than 1% per coital act, how many viruses initiate an abortive infection in the mucosa.

It has been possible to reproduce the transmission-linked genetic bottleneck in the non-human primate model of HIV-1 infection, where rhesus macaque monkeys are challenged repeatedly with low doses of SIV intra-vaginally or intra-rectally. Macaques challenged multiple times via the rectal route with a quasi-species of SIV_{mac251} or SIV_{smE660} were found, using the same SGA approach as in infected people, to be infected with a limited number of genetic variants – a majority with a single variant (Keele et al. 2009). The kinetics of virus replication in these animals resembled that observed in acutely infected people (Fiebig et al. 2003). A similar genetic bottleneck, with predominantly single variants establishing infection, was observed when macaques were challenged intra-vaginally or through the penile route, although both were significantly less efficient. Increasing the challenge dose via the intra-rectal route above 10⁷ viral RNA copies resulted in infection being established by multiple (>10) T/F variants, suggesting that in this model system the genetic bottleneck could be overcome by increasing the size of the input inoculum (Liu et al. 2010).

Evidence for both chance and selection influencing transmission

The question of whether HIV-1 transmission is predominantly a stochastic process, where a single genetic variant establishes infection simply because of the low probability of transmission, has been the focus of much debate over the last several years. Alternatively, certain viral phenotypes, which confer enhanced transmissibility on a viral variant, could be selected for during transmission and systemic spread.

It is very clear that some aspects of the transmission process do involve chance: the genetic variant must be present in the genital fluid of the transmitting partner at the time of intercourse; it must interact with the genital or rectal mucosa; it must cross the epithelial barrier and infect a susceptible CD4⁺ T cell; and it must have a sufficient number of secondary target cells for infection to spread and establish a localized and then a systemic infection (Figure 1; (Joseph et al. 2015)). Despite these stochastic aspects of transmission, there is strong evidence that selection pressure is applied and that viruses with specific traits are selected for during the transmission process.

HIV-1 encodes two envelope (Env) glycoproteins gp41 and gp120 that form hetero-trimers on the surface of the virus, where three molecules of the membrane-spanning gp41 anchor an equivalent number of gp120 molecules, through non-covalent associations, in the viral membrane (Hunter 1997). Initially synthesized as a single precursor gp160, which is proteolytically cleaved during transport to the cell surface, these two glycoproteins are critical for viral entry into a target cell. The surface protein, gp120, contains the receptor binding domains, interacting first with CD4 molecules that are expressed primarily on a subset of T cells, CD4⁺ T cells, and macrophages. CD4 binding induces a conformational change in the trimer, leading to interaction with a co-receptor and further conformational changes that allow gp41 to mediate fusion of the viral and target cell membranes (Wilén et al. 2012). Most viruses utilize the chemokine receptor, CCR5 (Deng et al. 1996; Choe et al. 1996; Dragic et al. 1996; Berger et al. 1999; Feng et al. 1996; Alkhatib et al. 1996), as their co-receptor but during chronic infection viruses can evolve to utilize a second chemokine receptor, CXCR4 (Coetzer et al. 2008; Regoes and Bonhoeffer 2005).

Initial evidence for selection came from the finding that the bulk of newly transmitted viruses utilized the CCR5 co-receptor, even if CXCR4 viruses were present in the transmitting partner, providing the first evidence that CXCR4 tropic viruses were selected against, while CCR5 tropic viruses were selected for, in transmission. The discovery that persons at high risk of HIV-1 infection and homozygous for a deletion of 32 amino acids in their CCR5 gene were protected from acquiring HIV-1 by mucosal exposure, provided further evidence that CXCR4 viruses were selected against during HIV-1 transmission and that predominantly CCR5-tropic viruses could infect by this route (Liu et al. 1996; Dean et al. 1996; Zimmerman et al. 1997; Samson et al. 1996; Michael et al. 1997). The propensity for CCR5-tropism remains unexplained (Margolis and Shattock 2006), but could be due to target cell availability at portals of entry (Liu et al. 2014). This would be consistent with the observation that CCR5⁺CXCR4⁺ CD4⁺ T cells are a minor population (<25%) in both the epidermis and dermis of inner and outer foreskin compared to CCR5⁺CXCR4⁻ and CCR5⁺CXCR4⁺ CD4⁺ T cells (Liu et al. 2014), and that CCR5 expression is high on the surface of human vaginal epithelial CD4⁺ T cells (Hladik et al. 2007). It is also consistent with observations in monkey challenge studies, where the number of CCR5⁺ T target cells in the mucosa correlated with susceptibility to infection (Pandrea et al. 2008; Pandrea and Apetrei 2010).

The concept of selection during transmission has also been supported by phylogenetic analyses of HIV-1 sequences from heterosexual transmission pairs, which suggest that evolution during chronic infection may reduce transmissibility of the virus and favor transmission of earlier less evolved variants from the transmitting partner. By calculating evolutionary distances of recipient and donor Env sequences to their most recent common ancestor for 10 subtype D and 10 subtype A linked transmission pairs, Sagar et al. provided the initial evidence that newly infecting (recipient) viruses were evolutionarily closer to the most recent common ancestor (MRCA) than transmitting partner (donor) viruses (Sagar et al. 2009). Consistent with the concept of transmission of less-evolved viruses, intra-host diversity was found to be greater than inter-host diversity in two separate cohorts infected with subtypes A or D and B (Redd et al. 2012; Alizon and Fraser 2013). Moreover, a longitudinal analysis of the *env* gene of viruses from donors prior to transmission, also found that the virus that established infection in the recipient more closely resembled earlier viruses in the donor than the viruses circulating at the time of transmission (Redd et al. 2012).

These observations have been supported by a more recent study that included genes outside of *env*. In an analysis of 137 epidemiologically linked clade C heterosexual transmission pairs, Carlson et al. demonstrated a selection bias in favor of cohort consensus amino acid residues and against non-consensus polymorphisms in Gag, Pol and Nef, suggesting a transmission advantage for variants with consensus amino acid residues in proteins outside of Env (Carlson et al. 2014). This was particularly obvious following deep sequencing of the donor quasi-species and the newly infecting viruses from 5 transmission pairs. As shown in Figure 2, the transmission efficiency of non-consensus polymorphisms was reduced by approximately 20% compared to consensus amino acids for residues present at both high and low frequencies in the donor virus population. Non-consensus polymorphisms were predicted to reduce the structural stability of viral proteins, consistent with reduced *in vivo*

replicative fitness in their presence. The selection pressure for consensus residues was influenced by gender, with female to male transmission imposing a greater selection bias on the virus than male to female transmission, suggesting that women are infected with less fit viruses than men. Interestingly, selection bias was reduced in men with genital ulcers and inflammation (GUI) and when the donor partner exhibited high viral load (Carlson et al. 2014). Both factors are known to increase the risk of infection and number of genetic variants transmitted (see above), demonstrating the interplay between factors that influence general susceptibility and stringency of the genetic bottleneck. Preferential transmission of viruses closer to consensus was confirmed over the full genome in the same cohort with six transmission pairs using SGA (Deymier et al. 2015). These findings suggest that diversification and adaptation to immune responses, which occur in the virus population during chronic infection, may hinder its ability to transmit. It is possible, therefore, that if a T/F virus establishes infection and remains in a reservoir that is produced sporadically or has a slow turnover rate, then these viruses over time will be present as minor variants in the host and will also retain the characteristics necessary to transmit again. Recent studies in the Amsterdam cohort, where the phylogenetic relationship of proviruses present in the viral reservoir following suppressive anti-retroviral treatment to viruses from several time points prior to treatment, are consistent with this hypothesis. In several individuals, viral reservoir sequences were PCR amplified that were highly related to viruses observed in acute/early infection, although in each case they were a minority of the population (Brodin et al. 2016).

Some of the first observations of a genetic bottleneck suggested that transmitted viruses were minor variants of the donor's plasma. In one of the initial studies that compared viral genetic diversity within and between partners in transmission pairs by analyzing virus from plasma, seminal fluid and seminal cells, the transmitted virus could be identified in both cell-free and cell-associated forms in the donor genital tract, and it was generally a minor variant of the genital tract (Zhu et al. 1996). A more recent analysis utilizing SGA of the V1-V4 region of Env from genital tract and plasma samples of eight subtype C infected heterosexual transmission pairs reported very similar results. It showed that, despite significant compartmentalization of viral genotypes with discrete populations within the genital compartment, the virus in the donor that most closely resembled the T/F was a minor variant, either of the genital tract or the plasma (Boeras et al. 2011). While genital tract enriched populations may be transient, and virus populations cannot be sampled precisely at the time of transmission (Anderson et al. 2010; Boeras et al. 2011), both studies do provide additional evidence in favor of HIV-1 selection during transmission.

Properties of the Transmitted/Founder Virus

Evidence of the genetic bottleneck and of selection during sexual transmission of HIV-1 has stimulated efforts to define biological characteristics of T/F viruses that could favor their transmission over a majority of the viruses that are circulating in the transmitting partner's quasi-species. To date, other than CCR5 tropism, no single trait has been consistently identified across the different studies and cohorts reported. In some respects, this could reflect the differences in the cohorts under study (e.g. MSM vs. heterosexual), as well as the stringency of the barriers to infection the virus must face (e.g. in the absence or presence of inflammation). Nevertheless, a number of properties have been linked to transmissibility

and, while these have been addressed in recent reviews (Joseph et al. 2015); Ende et al., 2017, in press), will be summarized briefly here.

Co-receptor utilization:

The observation that CCR5-tropic viruses are preferentially transmitted has been reproduced in most studies, including those where discrete T/F virus envelopes and full-length viruses were examined (Baalwa et al. 2013; Isaacman-Beck et al. 2009; Keele et al. 2008; Long et al. 2002; Parrish et al. 2013); however, this is not invariant, and infrequent CXCR4-tropic or dual-tropic transmitted strains have been observed. Although macrophages were once considered potential Trojan horses for carrying HIV-1 across the mucosa, it should be noted that T/F viral Envs mediate inefficient infection of macrophages and show a requirement for high levels of both CD4 and CCR5, with no evidence for preferential use of alternate coreceptors (Keele et al. 2008; Sagar et al. 2009; Salazar-Gonzalez et al. 2009; Isaacman-Beck et al. 2009; Alexander et al. 2010). These studies argue that neither infection of macrophages nor alternate coreceptor usage is advantageous for HIV-1 transmission.

Variable loop size and neutralization sensitivity:

A major clue that transmission might select for traits other than co-receptor usage came from a comparison of the viral Env sequences from both partners of seven subtype C and one subtype G HIV-1 transmission pairs. It was found that within each pair, whether male-to-female or female-to-male, the newly transmitted viruses encoded statistically shorter, less glycosylated V1-V4 regions than their chronic counterparts (Derdeyn et al. 2004), raising the possibility that more compact envelope glycoproteins better interacted with critical target cells in the genital mucosa. The observation was confirmed using SGA in an additional 10 subtype C transmission pairs (Haaland et al. 2009). While similar results were obtained in studies of subtype A infected sex-workers in Kenya and subtype D and A transmission pairs from the Rakai district of Uganda (Chohan et al. 2005; Sagar et al. 2009), they have not been seen in most studies of recently transmitted subtype B HIV-1 (Chohan et al. 2005; Frost et al. 2005; Wilen et al. 2011). However, in a study comparing the SGA-derived Env sequences from 135 acutely infected and 140 chronically clade B HIV infected individuals, statistically fewer N-linked glycosylation (PNLG) sites were found in the gp120s from early infection, with a trend towards fewer PNLG in the V1V2 loops and reduced V4 lengths (Gnanakaran et al. 2011).

An analysis of neutralization of subtype C heterosexually transmitted viruses demonstrated modestly increased sensitivity to antibodies in linked donor plasma taken near the time of transmission (Derdeyn et al. 2004; Deymier et al. 2015), though not to broadly neutralizing antibodies (Parrish et al. 2012) or pooled plasma (Derdeyn et al. 2004). It is possible that bound antibodies could enhance infection through capture by dendritic cell via Fc receptors in the mucosa of the new host, as has been reported for infected volunteers in the VAX004 vaccine trial, but this has not been demonstrated in non-vaccinated populations (Forthal et al. 2012). It is likely that donor antibody sensitivity reflects a surrogate marker of a different phenotype, such as mutational escape away from consensus, which in a recent study inversely correlated with donor antibody sensitivity over six subtype C transmission pairs (Deymier et al. 2015).

Interactions with the integrin $\alpha 4\beta 7$:

CD4⁺ T cells expressing $\alpha 4\beta 7$ home to mucosal sites, including the genital and gastrointestinal tract (Hawkins et al. 2000), and are highly susceptible to HIV-1 infection (Cicala et al. 2009). This susceptibility is likely facilitated by HIV-1 gp120 binding to $\alpha 4\beta 7$ via a motif in the second variable region, V2 (Arthos et al. 2008). A comparison of Envs from early in infection to later isolates from the same individual showed early high-affinity binding to $\alpha 4\beta 7$ that was lost over time. This appeared in part to be due to the absence of glycosylation at specific sites in V1 and V2 since mutation of these sites in the chronic envelopes increased $\alpha 4\beta 7$ binding (Nawaz et al. 2011). In addition, an analysis of viruses from the CAPRISA acute infection cohort from South Africa showed that dependence on $\alpha 4\beta 7$ for *in vitro* replication was high for T/F Env chimeras, particularly those encoding a P/SDI/V tri-peptide binding motif in the V2 region of gp120. This dependence on $\alpha 4\beta 7$ was lost during the first two months of infection, but regained at 39 months post infection for three individuals followed longitudinally (Richardson et al. 2015). An earlier comparison of subtype C T/F and chronic viruses had not observed differential inhibition of infection by a blocking antibody to $\alpha 4\beta 7$ (Parrish et al. 2012), however, dissecting inhibition from antibody binding activation of cells has complicated the interpretation of this data.

Despite the mixed results of *in vitro* studies, administering a blocking antibody to $\alpha 4\beta 7$ prior to SIV challenge in rhesus macaques decreased the number of animals infected and increased the number of challenges for infection to occur. Moreover, treated but infected animals showed a significant reduction in CD4⁺ T cells loss in gut-associated lymphoid tissue (GALT) and evidence for limited trafficking of infection out of the genital mucosa (Byraredy et al. 2014). Thus viruses with enhanced $\alpha 4\beta 7$ affinity may possess increased transmissibility through the increased efficiency by which virus infected cells are trafficked to the GALT.

Sensitivity to type I interferons:

The innate immune response, in particular the production of type 1 interferons (IFN), is very important in a number of viral infections including lentiviruses (Doyle et al. 2015). Treatment of rhesus macaques with IFN $\alpha 2$ increased the number of challenges required to establish systemic SIV_{mac} (Sandler et al. 2014) and SHIV infection (Veazey et al. 2016). However, while IFNs are upregulated in the early stages of SIV infection in macaques (Abel et al. 2005), a recent large study of acute infection found that prior to day 10, when plasma viremia was apparent, SIV_{mac239} down-regulated the IFN response in cells it infected and instead stimulated an inflammasome response (Barouch et al. 2016).

Nevertheless, a number of recent papers have presented evidence that T/F variants are relatively resistant to IFN compared to viruses from chronic infection (Parrish et al. 2013; Foster et al. 2016; Iyer et al. 2017). Although in a large study comparing T/F and chronic circulating viruses, subtype differences were observed. In this study, where subtype B T/F infectious molecular clones (IMCs) were less susceptible to IFN α , subtype C T/F and chronic variants exhibited similar sensitivity to interferon (Parrish et al. 2013). In contrast, in a comparison of subtype B and C T/F variants and their matched 6-month post-infection and chronic infection counterparts, the T/F isolates were found to be more resistant to IFN α .

(Fenton-May et al. 2013). A specific restriction factor associated with co-receptor usage, IFN-induced transmembrane protein 1 (IFITM1), determined the resistance phenotype of the T/F and 6-month virus pairs (Foster et al. 2016), though VPU-tetherin interactions have also been implicated as major determinants of resistance for some of these variants (Kmiec et al. 2016). Both interferon-induced restriction factors IFITM1 and tetherin act at the plasma membrane and interact with the viral Env, which has been associated with IFN resistance in an investigation of SHIVs passaged in rhesus macaque cells *in vitro* (Boyd et al. 2016). In addition, a recent comparison of viral outgrowth isolates from eight transmission pairs, where the transmitting partner had viral loads exceeding 1×10^5 copies/ml, showed that all of the isolates from acute plasma were more resistant to both IFN α and IFN β than those from the transmitting partner (Iyer et al. 2017).

However, not all studies have reported results consistent with these most recent observations. In an analysis of six subtype C transmission pairs, where IMCs representing the T/F virus from the newly infected partner and representative viruses from the transmitting partner were generated, replicative capacity (RC) was found to be positively associated with IFN α inhibition of replication, and a comparison of viruses matched for RC showed no consistent evidence of enhanced interferon resistance for T/F variants (Deymier et al. 2015). Furthermore, in an independent study, T/F isolates from 9 subtype B transmission pairs showed greater rather reduced sensitivity to IFN (Oberle et al. 2016), as did acute Env chimeras derived from 7 acute subtype B IDU infections when compared to chronic controls (Etemad et al. 2014). The conflicting results may stem from differences in the subjects under study, or the approaches taken to isolate infectious virus and assess IFN resistance. Additional studies where viruses from different HIV-1 subtypes and derived from both partners of transmission pairs very near the time of transmission are investigated will be critical to resolving the differences currently observed. Given the known impact of genital inflammation and ulcers in the uninfected partner, and VL in the chronically infected partner, on susceptibility to infection and the genetic bottleneck, it is likely these factors will need to be taken into account when comparing studies.

Infectivity and Replicative Capacity:

One of the most compelling hypotheses regarding HIV transmission proposes that T/F variants replicate faster than other variants, granting a competitive advantage during the initial events of viral growth and dissemination (Shaw and Hunter 2012). This would also be compatible with the selection bias for consensus amino acid residues, which are predicted to increase structural stability and presumably function of the Gag and Pol proteins (Carlson et al. 2014). In general, studies have compared both infectivity and replication, in single and multi-round infection assays, respectively. Evidence that transmitted variants have enhanced infectivity is inconsistent and varies between cohorts and studies (Parrish et al. 2013; Selhorst et al. 2017b; Deymier et al. 2014; Oberle et al. 2016; Iyer et al. 2017), but is generally quite subtle (2–3 fold) when it has been observed. Interestingly, an analysis of virus isolates and Env pseudoviruses from the CAPRISA 004 tenofovir gel trial showed that variants transmitted to women with genital inflammation were less infectious (Selhorst et al. 2017b). Genital ulceration and inflammation are known to increase the number of transmitting variants (Haaland et al. 2009) and decrease selection pressure (Carlson et al.

2014), consistent with this observation. For subtype B and C Env-pseudotyped (Isaacman-Beck et al. 2009; Oberle et al. 2016) and subtype B and C full-length (Parrish et al. 2013; Deymier et al. 2015; Yue et al. 2015; Ochsenbauer et al. 2012; Salazar-Gonzalez et al. 2009; Oberle et al. 2016) T/F variants, a 50–100-fold range of infectivity was found, similar to that seen in the non-transmitted variants. Chimeric viruses containing Gag from acute and early time points from subtype B (Brockman et al. 2010) and subtype C (Wright et al. 2010; Prince et al. 2012; Claiborne et al. 2015) strains also exhibited a broad range of RCs, which correlated well with those of IMCs derived from the same patients (Claiborne et al. 2015), suggesting that variants with relatively low and high RC *in vitro* have the potential to transmit. Similarly, most studies have not demonstrated a replicative advantage for transmitted variants measured in multiple round infections *in vitro*, instead showing transmission of viral variants with a range of RCs (Parrish et al. 2013; Deymier et al. 2015; Yue et al. 2015; Ochsenbauer et al. 2012; Salazar-Gonzalez et al. 2009; Oberle et al. 2016). Although, a recent study of eight subtype B and C transmission pairs did find that early isolates replicated somewhat (1.4-fold) higher than variants from matched donor partners (Iyer et al. 2017). Nevertheless, current data suggest that, in order to establish infection, the range of infectivity and RC, at least as measured *in vitro*, can be broad. However, as we will discuss below, the *in vitro* RC of the T/F virus can have a profound impact on both early pathogenesis and long-term trajectory of disease.

A Complex Interplay between Host Immunity and Transmitted Virus Phenotype Defines Viral Control and Disease Progression

It is clear that traits of the transmitted virus influence the course of the disease. Despite human immunogenetic variability, high viral mutation rates leading to adaptation, and a restrictive genetic bottleneck during transmission, VL set-point in the donor correlates with that in the infected partner, although it is significantly modulated by the sex and immune response genes of the newly infected individual (Hecht et al. 2010; Yue et al. 2013). The heritability of VL suggests that disease progression itself can have a heritable component (Fraser et al. 2014) since VL is a strong predictor of disease progression (Mellors et al. 1995).

As we discuss in more detail below, the cellular immune response of a newly infected individual, programmed by their human leukocyte antigen (HLA) class I alleles, imposes selection pressures on the virus that result in the outgrowth of viruses with mutations in the controlling epitopes. The impact of these mutations on the T/F virus following transmission is complex. If these mutations are in epitopes normally recognized by the newly infected individuals class I alleles, they can reduce the ability of the immune system to control the replication of the virus and, therefore, result in enhanced disease progression (Carlson et al. 2016; Crawford et al. 2009; Monaco et al. 2016). On the other hand, although beneficial for the survival and propagation of the virus in the chronically infected partner, these mutations can negatively impact the replicative fitness of the virus when it is transmitted to an individual that does not share HLA-I alleles that recognize the epitope (Brockman et al. 2010; Chopera et al. 2008; Goepfert et al. 2008). The remainder of this review will discuss this complex interaction between the transmitted virus and its new host.

Host Control of Virus Replication:

The cellular immune response plays a central role in controlling HIV-1 viral replication. In humans, the most compelling evidence in favor of this role comes from the consistent observation of a temporal association between the rapid decline in viremia during acute infection and the increase in numbers of HIV-specific cytotoxic T lymphocytes (CTLs) in the blood (Koup et al. 1994; Borrow et al. 1994). Studies in a non-human primate model of SIV or SHIV infection have provided the most direct evidence by depleting CD8⁺ T cells at different stages of infection. During acute infection, transient depletion of CD8⁺ T cells leads to increased plasma and cell-associated virus levels in both the peripheral blood and lymphoid tissues along with prolonged depletion of CD4⁺ T cells and accelerated disease progression (Matano et al. 1998; Schmitz et al. 1999). Similarly, depletion of CD8⁺ T cells during chronic infection results in a rapid increase in viremia that is again suppressed with the reappearance of SIV-specific CD8⁺ T cells (Schmitz et al. 1999; Jin et al. 1999). More recently, the role of CTLs in controlling viremia has also been demonstrated even in the presence of antiretroviral treatment (ART). Depletion of CD8⁺ cells during ART significantly increased plasma VL and reconstitution of these cells was associated with re-establishment of viral control, providing a rationale for the administration of therapeutic vaccines in conjunction with ART (Cartwright et al. 2016).

Selection of CTL escape mutations:

The changes in viremia associated with the presence or expansion of HIV-specific CTLs shows that these cells exert immunologic pressure on the virus, though they are still unable to clear or completely control the infection in the majority of infected individuals. A clear manifestation of this immunologic pressure is the appearance of escape mutations. These mutations have been identified both in acute and chronic infection and in all HIV-1 proteins, including accessory proteins, which indicates that the CTLs are constantly and widely targeting the virus during HIV-1 infection (Borrow et al. 1997; Goulder et al. 1997).

CTL escape mutations are thus able to release the pressure exerted by HIV-specific CTLs, and function at three different stages during the process of antigen presentation. First, these mutations can prevent the processing of the protein via the proteasome, abrogating the generation of the epitope before being loaded onto the HLA Class I molecule. Second, CTL escape mutations can compromise the loading of the HLA Class I molecule, which occurs in the endoplasmic reticulum before the loaded complex travels to the cell surface, by reducing its binding affinity for the epitope (Yokomaku et al. 2004). Finally, these mutations can reduce or prevent the interaction of the T Cell Receptor (TCR) with the HLA Class I-epitope complex (Iglesias et al. 2011).

While initial studies focused on mutations identified by subsequent increases in viremia in individuals harboring a particular HLA-I allele, CTL escape mutations have been identified more recently in population analyses using statistical methods. This approach is able to identify HIV-1 polymorphisms that are significantly more prevalent in individuals harboring a particular HLA-I allele, while at the same time correcting for covarying sites, linkage disequilibrium among HLA-I alleles, and mutations that could have arisen during the

evolutionary history of the virus instead of in response to HLA-mediated immune pressure (Bhattacharya et al. 2007; Carlson et al. 2008).

Impact of CTL escape mutations on chronic and acute HIV-1 infection:

CTL escape mutations are rapidly selected after the cytotoxic immune response is mounted (Fischer et al. 2010; Henn et al. 2012), and the time in which these mutations arise has been shown to be much faster in response to protective HLA alleles such as HLA B*57 or HLA B*27 (Roberts et al. 2015). Although these mutations confer a fitness advantage to the virus by preventing CTLs from targeting infected cells, they usually carry a significant replicative fitness cost (Martinez-Picado et al. 2006). However, because HIV-1 is a chronic disease, with continued virus replication, secondary or compensatory mutations frequently arise that reduce the impact of CTL escape mutations on replication, and allows for their maintenance (Brockman et al. 2007; Schneidewind et al. 2007).

Direct evidence for an impact on HIV-1 disease following transmission of CTL escape mutations has come from mother-to-child transmission (Goulder et al. 2001) as well as from serodiscordant couples (Goepfert et al. 2008; Crawford et al. 2009; Monaco et al. 2016; Carlson et al. 2016). In both cases, the viral quasi-species present in the donor at the time of transmission can be studied in order to distinguish transmitted mutations from those that arise early in the newly infected individual. Even though HLA B*27 and HLA B*57 are generally associated with protection against disease progression in HIV-infected individuals (Kaslow et al. 1996; Fellay et al. 2007; Kiepiela et al. 2007; Schneidewind et al. 2007), these earlier studies showed that transmitted CTL escape mutations, and the pre-adapted epitopes associated with these alleles, are linked to rapid loss of control of viral replication and accelerated disease progression in HLA-matched individuals (Goulder et al. 2001; Crawford et al. 2009). These findings highlighted the fact that, when transmitted to HLA-matched individuals, CTL escape mutations abrogate protection against disease progression.

Population studies of the prevalence of CTL escape mutations indicate that these mutations are accumulating both over time (Cotton et al. 2014; Dilek et al. 2008) and in relation to HLA allele prevalence (Kawashima et al. 2009). This phenomenon can lead to the circulation of viruses that are potentially already adapted to the HLA alleles in the HIV-1 negative population. While a study of the North American epidemic did not observe significant adaptation over time in circulating viruses over 20 years, this could have been related to the high HLA diversity and low genetic frequency of each allele in this population (Cotton et al. 2014). Since transmission of pre-adapted viruses compromises the ability of the CTL immune response to target these viruses in the newly-infected individual, this raises the possibility that pre-adaptation of the T/F virus could have a significant impact on both viral control and disease progression.

This question was answered in recent studies of epidemiologically linked HIV-1 transmission pairs from a Zambian acute infection cohort, where the degree of preadaptation of the transmitted viruses was accurately estimated by focusing on polymorphisms present both in the donor and in the recipient. These polymorphisms were located both in positions statistically linked to the HLA alleles of the recipient and also in epitopes with a higher predicted HLA-I binding affinity. This analysis showed that approximately one-third of

possible HLA-linked target sites were already adapted in T/F viruses and that this pre-adaptation compromised early immune recognition of the transmitted virus. Evaluation of CTL responses against adapted (meaning harboring HLA-linked mutations) and non-adapted epitopes across the entire Gag protein according to each individual's HLA alleles showed that adapted epitopes were significantly less recognized than non-adapted epitopes and, in the cases where an IFN- γ response was detected, it was of a lower magnitude. Moreover, in individuals that were infected with viruses where 50% of the HLA-linked target sites were pre-adapted, significantly fewer and less potent IFN- γ responses were elicited (Monaco et al. 2016). A parallel study, in which Carlson and colleagues used a mathematical model to estimate autologous adaptation of the transmitted virus, showed that CTLs targeting adapted epitopes had reduced antigen sensitivity and killing capacity when compared to those targeting non-adapted epitopes in both structural and accessory proteins (Carlson et al. 2016).

The degree of pre-adaptation in the Gag protein of a transmitted virus was also associated with higher viral loads and faster decline of CD4⁺ T cells (Monaco et al. 2016), and this association was also true when the analysis was extended to Gag, Pol and Nef proteins (Carlson et al. 2016). However, this association with VL was stronger after accounting for polymorphisms that were not linked to the HLA molecules of the newly infected individual (non-associated polymorphisms), which conversely associated with lower VL and slower decline of CD4⁺ T cells. These results illustrate how HIV-1 disease progression is ultimately dictated by the balance between the two opposing forces of transmitted pre-adaptation, which determines the number and quality of epitopes effectively targeted—both initially and subsequently during the course of infection—and non-associated polymorphisms, which likely lead to reduced viral replicative fitness (Monaco et al. 2016) (Figure 3).

Importantly, the role of pre-adaptation and transmitted non-associated polymorphisms on viral control and disease progression remained significant in the context of other factors known to influence clinical outcomes. In the case of disease progression, a ratio between pre-adaptation and transmitted non-associated polymorphisms was the strongest predictor of decline of CD4⁺ T cells, followed by set-point VL and RC. The impact of pre-adaptation may reflect the reduced capacity of the immune system to target the virus both early in infection as well as late in infection, as the virus continues to adapt.

Taken together, these recent studies have significant implications for vaccine development. Immunogens harboring escape mutations may not be able to effectively prime an immune response. On the other hand, efficiently primed responses targeting epitopes where CTL escape mutations are frequently transmitted in a population may be less able to control those pre-adapted viruses. In this context, the use of immunogens that focus on inducing CTLs against conserved regions of the HIV-1 proteome where selection and transmission of CTL escape mutations are less frequent could help overcome these challenges.

Impact of immune selection on replicative capacity and subsequent disease progression:

In contrast to the disease-enhancing effects of CTL escape mutations that represent preadaptation in the new host, CTL escape mutations transmitted to HLA mismatched individuals show the opposite effect by providing an advantage for the newly infected

individual that is associated with a loss of replicative fitness. The fact that these detrimental mutations usually revert or are compensated for shortly after transmission is consistent with their impact on virus replication since natural selection favors viruses with higher replicative fitness (Crawford et al. 2007; Leslie et al. 2004; Schneidewind et al. 2009).

Since the most protective HLA alleles, HLA B*57 and B*27, target epitopes in the p24 capsid protein of HIV-1, initial studies focused on the impact of escape mutations in this region of the viral proteome on virus replication. Brockman et al. demonstrated that an escape mutation located in the B*57 TW10 epitope in Gag, T₂₄₂N, reduced replicative capacity of NL4–3 but this defect could be partially compensated by mutations at a second site in p24 (Brockman et al. 2007). Similarly, Crawford et al. demonstrated that the A₁₆₃G escape mutation in the B*5703 KF11 epitope in Gag impaired replication but could be effectively compensated by an accompanying S₁₆₅N mutation. In each case, individuals with mutations that compensated for the replication defect exhibited higher viral loads than those harboring just the escape mutation itself, correlating *in vitro* replication to *in vivo* levels of virus. Consistent with this, the *in vitro* RC of chimeric NL4–3 viruses encoding the *gag* gene (and a small region of protease) of viruses derived from individuals exhibiting elite control of VL was significantly lower than that of viruses derived from chronic progressors (Miura et al. 2009; Miura et al. 2010). In a large study of over 800 subtype B chronically infected individuals for whom Gag-Pro chimeras were constructed, a modest positive correlation was observed between RC and VL, while a negative correlation was observed between RC and CD4⁺ T cell count, consistent with RC influencing CD4⁺ T cell decline (Brockman et al. 2010). Similar results were observed in a South African subtype C cohort (Wright et al. 2010).

In two studies of subtype C acutely infected individuals, higher numbers of transmitted CTL escape mutations in Gag, but not in Nef, were associated with lower VLs and higher CD4⁺ T cell counts in the newly infected recipient (Goepfert et al. 2008; Chopera et al. 2008). These data suggested that transmission of CTL escape mutations in the *gag* gene of the T/F virus might impact both viral control and disease progression through reduced RC. In an initial study of over 100 acutely infected Zambians, the RC conferred by transmitted subtype C *gag* sequences was moderately correlated with set-point VL. Moreover, individuals harboring low RC viruses exhibited significantly slower CD4⁺ T cell decline during the first three years after transmission compared to those harboring high RC viruses (Prince et al. 2012). Studies with similarly constructed Gag-Pro chimeric viruses derived from recently infected individuals in South Africa also showed a trend towards more rapid CD4⁺ T cell decline for high RC viruses (Wright et al. 2011).

A follow-up study also in acutely infected Zambians showed that RC of the transmitted variants predicted CD4 decline independently of other risk factors, such as VL and protective HLA alleles, a finding also confirmed in samples from the CAPRISA 004 trial (Selhorst et al. 2017a). The RCs of the Gag-Pro chimeric viruses studied correlated well with those of IMCs derived from the same patients (Claiborne et al. 2015). Infection with a high RC virus was associated with profound changes in immune function compared to infection with a low RC virus. For high RC viruses, high levels of inflammatory cytokines and markers of bacterial translocation were observed very early (~45 days after the

estimated date of HIV-1 infection), as were activation/proliferation markers (CD38, HLA-DR, Ki-67) and markers of T-cell dysfunction (PD-1) in both CD4 and CD8 T cell populations. In addition, elevated levels of HIV-1 proviral DNA was observed in naïve and central memory CD4⁺ T cells. All of these features appeared to contribute to more rapid disease progression (Claiborne et al. 2015), indicating that the replication phenotype of the T/F virus can have a profound impact on the earliest virus-host interactions that then define the trajectory of disease.

Conclusions

The past several years have seen significant progress in understanding the virology of both HIV-1 transmission and subsequent disease progression. It is established that in most instances of HIV-1 sexual transmission, a single T/F variant, or a limited number of variants, from the diverse quasi-species present in the transmitting partner, establishes systemic infection. What is less clear, in the context of the level of virus exposure common during sexual activity, is how many variants initiate localized replication, and how many of those may fail to propagate to more distal sites. Nor is it clear, given the different selection pressures in the presence and absence of mucosal infections and inflammation, for example, whether any one property, such as *in vivo* RC or reduced sensitivity to IFN, will set apart T/F viruses from their non-transmitted counterparts. Clearly, based on the spectrum of *in vitro* RC observed for T/F viruses, it seems likely that the bar for transmission can be quite low. It will be interesting to observe whether *in vivo* models such as the humanized mouse or *in vitro* mucosal tissue explant models will shed additional light on viral properties that facilitate transmission.

While selective bias does result in the partial loss of non-consensus polymorphisms (mutations) during transmission, a majority (many of which represent immune response escape mutations) are present in the T/F variant. Those that impact virus replication in a negative fashion, and result in viruses with low RC, can be highly protective to the newly infected host in terms of disease progression, by inducing lower levels of inflammation and immune dysfunction. They also result in lower levels of proviral DNA in naïve and memory CD4⁺ T cells early in infection, which may mean smaller viral reservoirs post-ART and a greater opportunity for studies aimed at long-term remission (or cure). In contrast, mutations in epitopes that are normally targets for the immune response genes of the newly infected individual can have an opposite effect on disease progression by reducing immune recognition, target cell killing, and virus control. It is the balance of this complex interplay between the phenotype defined by viral genetics and host immunogenetics that ultimately defines the trajectory of HIV-1 disease in a newly infected individual, with the virus genotype playing a much greater role than previously envisaged.

References

- Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ (2005) Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. *J Virol* 79 (19):12164–12172. doi:79/19/12164 [pii] 10.1128/JVI.79.19.12164-12172.2005 [PubMed: 16160143]

- Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS, Treurnicht FK, Keele BF, Wood N, Salazar-Gonzalez JF, Bhattacharya T, Chu H, Hoffman I, Galvin S, Mapanje C, Kazembe P, Thebus R, Fiscus S, Hide W, Cohen MS, Karim SA, Haynes BF, Shaw GM, Hahn BH, Korber BT, Swanstrom R, Williamson C (2009) Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. *J Virol* 83 (8):3556–3567. doi:JV1.02132–08 [pii] 10.1128/JVI.02132-08 [PubMed: 19193811]
- Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E (2010) Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. *J Virol* 84 (8):4100–4104. doi:JV1.02068–09 [pii] 10.1128/JVI.02068-09 [PubMed: 20147398]
- Alizon S, Fraser C (2013) Within-host and between-host evolutionary rates across the HIV-1 genome. *Retrovirology* 10:49. doi:10.1186/1742-4690-10-49 [PubMed: 23639104]
- Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science* 272 (5270):1955–1958 [PubMed: 8658171]
- Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, Padavattan N, Ismail N, Moodley A, Sabatini ME, Ghebremichael MS, Nusbaum C, Huttenhower C, Virgin HW, Ndung'u T, Dong KL, Walker BD, Fichorova RN, Kwon DS (2015) Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. *Immunity* 42 (5):965–976. doi:10.1016/j.immuni.2015.04.019 [PubMed: 25992865]
- Anderson JA, Ping LH, Dibben O, Jabara CB, Arney L, Kincer L, Tang Y, Hobbs M, Hoffman I, Kazembe P, Jones CD, Borrow P, Fiscus S, Cohen MS, Swanstrom R (2010) HIV-1 Populations in Semen Arise through Multiple Mechanisms. *PLoS pathogens* 6 (8):e1001053. doi:10.1371/journal.ppat.1001053 [PubMed: 20808902]
- Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, McLaughlin S, Pascuccio M, Gopaul R, McNally J, Cruz CC, Censoplano N, Chung E, Reitano KN, Kottilil S, Goode DJ, Fauci AS (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. *Nat Immunol* 9 (3):301–309. doi:ni1566 [pii] 10.1038/ni1566 [PubMed: 18264102]
- Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. *PLoS Med* 2 (11):e298. doi:05-PLME-RA-0310R1 [pii] 10.1371/journal.pmed.0020298 [PubMed: 16231970]
- Baalwa J, Wang S, Parrish NF, Decker JM, Keele BF, Learn GH, Yue L, Ruzagira E, Ssemwanga D, Kamali A, Amornkul PN, Price MA, Kappes JC, Karita E, Kaleebu P, Sanders E, Gilmour J, Allen S, Hunter E, Montefiori DC, Haynes BF, Cormier E, Hahn BH, Shaw GM (2013) Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. *Virology* 436 (1):33–48. doi:10.1016/j.virol.2012.10.009 [PubMed: 23123038]
- Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. *Lancet* 369 (9562):643–656. doi:S0140–6736(07)60312–2 [pii] 10.1016/S0140-6736(07)60312-2 [PubMed: 17321310]
- Barouch DH, Ghneim K, Bosche WJ, Li Y, Berkemeier B, Hull M, Bhattacharyya S, Cameron M, Liu J, Smith K, Borducchi E, Cabral C, Peter L, Brinkman A, Shetty M, Li H, Gittens C, Baker C, Wagner W, Lewis MG, Colantonio A, Kang HJ, Li W, Lifson JD, Piatak M, Jr., Sekaly RP (2016) Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. *Cell* 165 (3):656–667. doi:10.1016/j.cell.2016.03.021 [PubMed: 27085913]
- Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. *Annu Rev Immunol* 17:657–700. doi:10.1146/annurev.immunol.17.1.657 [PubMed: 10358771]
- Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C, Carlson J, Yusim K, McMahon B, Gaschen B, Mallal S, Mullins JI, Nickle DC, Herbeck J, Rousseau C, Learn GH, Miura T, Brander C, Walker B, Korber B (2007) Founder effects in the assessment of HIV polymorphisms

and HLA allele associations. *Science* 315 (5818):1583–1586. doi:10.1126/science.1131528 [PubMed: 17363674]

- Blaschitz C, Raffatellu M (2010) Th17 Cytokines and the Gut Mucosal Barrier. *Journal of Clinical Immunology* 30 (2):196–203. doi:10.1007/s10875-010-9368-7 [PubMed: 20127275]
- Boeras DI, Hraber PT, Hurlston M, Evans-Strickfaden T, Bhattachary T, Giorgi EE, Mulenga J, Karita E, Korber BT, Allen S, Hart CE, Derdeyn CA, Hunter E (2011) Role of donor genital tract HIV-1 diversity in the transmission bottleneck. *PNAS* In Press
- Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J Virol* 68 (9):6103–6110 [PubMed: 8057491]
- Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nat Med* 3 (2):205–211 [PubMed: 9018240]
- Boyd DF, Sharma A, Humes D, Cheng-Mayer C, Overbaugh J (2016) Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon-alpha Resistance. *PLoS Pathog* 12 (7):e1005727. doi:10.1371/journal.ppat.1005727 [PubMed: 27399306]
- Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Legault M, Tremblay C, Charest H, Wainberg MA (2007) High rates of forward transmission events after acute/early HIV-1 infection. *J Infect Dis* 195 (7):951–959. doi:10.1086/512088 [PubMed: 17330784]
- Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, Kadie CM, Carlson JM, Markle TJ, Streeck H, Kelleher AD, Markowitz M, Jessen H, Rosenberg E, Altfeld M, Harrigan PR, Heckerman D, Walker BD, Allen TM (2010) Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. *J Virol* 84 (22):11937–11949. doi:10.1128/JVI.01086-10 [PubMed: 20810731]
- Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, Ryvkin F, Derdeyn CA, Allen S, Hunter E, Mulenga J, Goepfert PA, Walker BD, Allen TM (2007) Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. *J Virol* 81 (22):12608–12618. doi:10.1128/JVI.01369-07 [PubMed: 17728232]
- Brodin J, Zanini F, Thebo L, Lanz C, Bratt G, Neher RA, Albert J (2016) Establishment and stability of the latent HIV-1 DNA reservoir. *eLife* 5. doi:10.7554/eLife.18889
- Byraredy SN, Kallam B, Arthos J, Cicala C, Nawaz F, Hiatt J, Kersh EN, McNicholl JM, Hanson D, Reimann KA, Brameier M, Walter L, Rogers K, Mayne AE, Dunbar P, Villinger T, Little D, Parslow TG, Santangelo PJ, Villinger F, Fauci AS, Ansari AA (2014) Targeting alpha4beta7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. *Nat Med* 20 (12):1397–1400. doi:10.1038/nm.3715 [PubMed: 25419708]
- Carlson JM, Brumme ZL, Rousseau CM, Brumme CJ, Matthews P, Kadie C, Mullins JI, Walker BD, Harrigan PR, Goulder PJ, Heckerman D (2008) Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. *PLoS computational biology* 4 (11):e1000225. doi:10.1371/journal.pcbi.1000225 [PubMed: 19023406]
- Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA (2016) Impact of pre-adapted HIV transmission. *Nat Med* 22 (6):606–613. doi:10.1038/nm.4100 [PubMed: 27183217]
- Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, Deymier MJ, Ende ZS, Klatt NR, DeZiel CE, Lin TH, Peng J, Seese AM, Shapiro R, Frater J, Ndung'u T, Tang J, Goepfert P, Gilmour J, Price MA, Kilembe W, Heckerman D, Goulder PJ, Allen TM, Allen S, Hunter E (2014) HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. *Science* 345 (6193):1254031. doi:10.1126/science.1254031 [PubMed: 25013080]
- Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, Lawson BO, Nega M, Easley K, Schmitz JE, Bosinger SE, Paiardini M, Chahroudi A, Vanderford TH, Estes JD, Lifson JD,

- Derdeyn CA, Silvestri G (2016) CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. *Immunity* 45 (3):656–668. doi:10.1016/j.immuni.2016.08.018 [PubMed: 27653601]
- Cecchinato V, Franchini G (2010) Th17 cells in pathogenic SIV infection of macaques. *Current opinion in HIV and AIDS* 5 (2):141–145. doi:10.1097/COH.0b013e32833653ec [PubMed: 20543591]
- Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell* 85 (7):1135–1148 [PubMed: 8674119]
- Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J (2005) Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. *J Virol* 79 (10):6528–6531. doi:10.1128/JVI.79.10.6528-6531.2005 [PubMed: 15858037]
- Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, Seoighe C, Treurnicht F, de Rosa DA, Hide W, Karim SA, Gray CM, Williamson C, Team CS (2008) Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. *PLoS Pathog* 4 (3):e1000033. doi:10.1371/journal.ppat.1000033 [PubMed: 18369479]
- Cicala C, Martinelli E, McNally JP, Goode DJ, Gopal R, Hiatt J, Jelacic K, Kottlil S, Macleod K, O'Shea A, Patel N, Van Ryk D, Wei D, Pascuccio M, Yi L, McKinnon L, Izulla P, Kimani J, Kaul R, Fauci AS, Arthos J (2009) The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. *Proc Natl Acad Sci U S A* 106 (49):20877–20882. doi:10.1073/pnas.0911796106 [PubMed: 19933330]
- Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, Kopycinski J, Deymier MJ, Vanderford TH, Nganou-Makamdop K, Ende Z, Brooks K, Tang J, Yu T, Lakhi S, Kilembe W, Silvestri G, Douek D, Goepfert PA, Price MA, Allen SA, Paiardini M, Altfeld M, Gilmour J, Hunter E (2015) Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. *Proc Natl Acad Sci U S A* 112 (12):E1480–1489. doi:10.1073/pnas.1421607112 [PubMed: 25730868]
- Coetzer M, Nedellec R, Salkowitz J, McLaughlin S, Liu Y, Heath L, Mullins JJ, Mosier DE (2008) Evolution of CCR5 use before and during coreceptor switching. *J Virol* 82 (23):11758–11766. doi:10.1128/JVI.01141-08 [PubMed: 18815295]
- Cotton LA, Kuang XT, Le AQ, Carlson JM, Chan B, Chopera DR, Brumme CJ, Markle TJ, Martin E, Shahid A, Anmole G, Mwimanzi P, Nassab P, Penney KA, Rahman MA, Milloy MJ, Schechter MT, Markowitz M, Carrington M, Walker BD, Wagner T, Buchbinder S, Fuchs J, Koblin B, Mayer KH, Harrigan PR, Brockman MA, Poon AF, Brumme ZL (2014) Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic. *PLoS genetics* 10 (4):e1004295. doi:10.1371/journal.pgen.1004295 [PubMed: 24762668]
- Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, Tang J, Farmer P, Ndung'u T, Lakhi S, Gilmour J, Goepfert P, Walker BD, Kaslow R, Mulenga J, Allen S, Goulder PJ, Hunter E (2009) Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. *J Exp Med* 206 (4):909–921. doi:10.1084/jem.20081984 [PubMed: 19307327]
- Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, Reddy S, van der Stok M, Mncube Z, Brander C, Rousseau C, Mullins JJ, Kaslow R, Goepfert P, Allen S, Hunter E, Mulenga J, Kiepiela P, Walker BD, Goulder PJ (2007) Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. *J Virol* 81 (15):8346–8351. doi:10.1128/JVI.00465-07 [PubMed: 17507468]
- Dandekar S, George MD, Baumler AJ (2010) Th17 cells, HIV and the gut mucosal barrier. *Curr Opin HIV AIDS* 5 (2):173–178. doi:10.1097/COH.0b013e328335eda3 [PubMed: 20543596]
- Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter

- AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. *Science* 273 (5283):1856–1862 [PubMed: 8791590]
- Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR (1996) Identification of a major co-receptor for primary isolates of HIV-1. *Nature* 381 (6584):661–666. doi: 10.1038/381661a0 [PubMed: 8649511]
- Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. *Science* 303 (5666):2019–2022. doi:10.1126/science.1093137303/5666/2019 [pii] [PubMed: 15044802]
- Deymier MJ, Claiborne DT, Ende Z, Ratner HK, Kilembe W, Allen S, Hunter E (2014) Particle infectivity of HIV-1 full-length genome infectious molecular clones in a subtype C heterosexual transmission pair following high fidelity amplification and unbiased cloning. *Virology* 468–470:454–461. doi:10.1016/j.virol.2014.08.018 [PubMed: 25243334]
- Deymier MJ, Ende Z, Fenton-May AE, Dilemnia DA, Kilembe W, Allen SA, Borrow P, Hunter E (2015) Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-alpha Resistance. *PLoS Pathog* 11 (9):e1005154. doi: 10.1371/journal.ppat.1005154 [PubMed: 26378795]
- Dilemnia DA, Jones L, Rodriguez S, Turk G, Rubio AE, Pampuro S, Gomez-Carrillo M, Bautista CT, Deluchi G, Benetucci J, Lasala MB, Lourtou L, Losso MH, Perez H, Cahn P, Salomon H (2008) HLA-driven convergence of HIV-1 viral subtypes B and F toward the adaptation to immune responses in human populations. *PLoS One* 3 (10):e3429. doi:10.1371/journal.pone.0003429 [PubMed: 18941505]
- Doyle T, Goujon C, Malim MH (2015) HIV-1 and interferons: who's interfering with whom? *Nat Rev Microbiol* 13 (7):403–413. doi:10.1038/nrmicro3449 [PubMed: 25915633]
- Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayan C, Maddon PJ, Koup RA, Moore JP, Paxton WA (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. *Nature* 381 (6584):667–673. doi:10.1038/381667a0 [PubMed: 8649512]
- Ende Z, Deymier M, Hunter E (2017) Virologic Aspects of Mucosal Transmission In: Mestecky J, Veazey R (eds) *Mucosal Immunology of HIV/SIV*. Bentham Science, p
- Etemad B, Gonzalez OA, White L, Laeyendecker O, Kirk GD, Mehta S, Sagar M (2014) Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users. *Retrovirology* 11:106. doi:10.1186/s12977-014-0106-8 [PubMed: 25430652]
- Evans DT, Silvestri G (2013) Nonhuman primate models in AIDS research. *Curr Opin HIV AIDS* 8 (4):255–261. doi:10.1097/COH.0b013e328361cee8 [PubMed: 23615116]
- Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB (2007) A whole-genome association study of major determinants for host control of HIV-1. *Science* 317 (5840):944–947. doi:1143767 [pii] 10.1126/science.1143767 [PubMed: 17641165]
- Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* 272 (5263):872–877 [PubMed: 8629022]
- Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P (2013) Relative resistance of HIV-1 founder viruses to control by interferon-alpha. *Retrovirology* 10:146. doi:10.1186/1742-4690-10-146 [PubMed: 24299076]
- Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, Mulenga J, Kasolo F, Vermund SH, Aldrovandi GM (2001) Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. *AIDS Res Hum Retroviruses* 17 (10):901–910. doi:10.1089/088922201750290023 [PubMed: 11461676]
- Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Poddada L, Heldebrandt C, Smith R, Conrad A, Kleinman SH, Busch MP (2003) Dynamics of HIV viremia and antibody

seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. *AIDS* 17 (13):1871–1879. doi:10.1097/01.aids.0000076308.76477.b8 [PubMed: 12960819]

Fischer W, Ganusov VV, Giorgi EE, Hraber PT, Keele BF, Leitner T, Han CS, Gleasner CD, Green L, Lo CC, Nag A, Wallstrom TC, Wang S, McMichael AJ, Haynes BF, Hahn BH, Perelson AS, Borrow P, Shaw GM, Bhattacharya T, Korber BT (2010) Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. *PLoS One* 5 (8):e12303. doi:10.1371/journal.pone.0012303 [PubMed: 20808830]

Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB (2012) Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. *Blood* 120 (14):2836–2842. doi:10.1182/blood-2012-05-431361 [PubMed: 22915639]

Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, Kellam P, Finzi A, Borrow P, Hahn BH, Neil SJ (2016) Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. *Cell host & microbe* 20 (4):429–442. doi:10.1016/j.chom.2016.08.006 [PubMed: 27640936]

Fraser C, Lythgoe K, Leventhal GE, Shirreff G, Hollingsworth TD, Alizon S, Bonhoeffer S (2014) Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. *Science* 343 (6177):1243727. doi:10.1126/science.1243727 [PubMed: 24653038]

Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ, Little SJ, Richman DD (2005) Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. *J Virol* 79 (10):6523–6527. doi:10.1128/JVI.79.10.6523-6527.2005 [PubMed: 15858036]

Galvin SR, Cohen MS (2004) The role of sexually transmitted diseases in HIV transmission. *Nat Rev Microbiol* 2 (1):33–42. doi:10.1038/nrmicro794 [PubMed: 15035007]

Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B (2011) Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections. *PLoS pathogens* 7 (9):e1002209. doi:10.1371/journal.ppat.1002209 [PubMed: 21980282]

Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, Carlson JM, Derdeyn CA, Tang J, Kaslow RA, Bansal A, Yusim K, Heckerman D, Mulenga J, Allen S, Goulder PJ, Hunter E (2008) Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. *The Journal of experimental medicine* 205 (5):1009–1017. doi:10.1084/jem.20072457 [PubMed: 18426987]

Gosmann C, Anahtar MN, Handley SA, Farcasanu M, Abu-Ali G, Bowman BA, Padavattan N, Desai C, Droit L, Moodley A, Dong M, Chen Y, Ismail N, Ndung'u T, Ghebremichael MS, Wesemann DR, Mitchell C, Dong KL, Huttenhower C, Walker BD, Virgin HW, Kwon DS (2017) Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. *Immunity* 46 (1):29–37. doi:10.1016/j.immuni.2016.12.013 [PubMed: 28087240]

Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M, He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIntosh K, Korber BT, Walker BD (2001) Evolution and transmission of stable CTL escape mutations in HIV infection. *Nature* 412 (6844):334–338. doi:10.1038/35085576 [PubMed: 11460164]

Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. *Nat Med* 3 (2):212–217 [PubMed: 9018241]

Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. *Lancet* 369 (9562):657–666. doi:10.1016/S0140-6736(07)60313-4 [PubMed: 17321311]

- Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, Nalugoda F, Kiddugavu M, Sewankambo N, Quinn TC, Reynolds SJ, Wawer MJ (2005) Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. *Lancet* 366 (9492):1182–1188. doi: 10.1016/S0140-6736(05)67481-8 [PubMed: 16198767]
- Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM, Hahn BH, Allen SA, Derdeyn CA, Hunter E (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. *PLoS Pathog* 5 (1):e1000274. doi:10.1371/journal.ppat.1000274 [PubMed: 19165325]
- Hahn BH, Shaw GM, De Cock KM, Sharp PM (2000) AIDS as a zoonosis: scientific and public health implications. *Science* 287 (5453):607–614 [PubMed: 10649986]
- Hatzioannou T, Evans DT (2012) Animal models for HIV/AIDS research. *Nat Rev Microbiol* 10 (12): 852–867. doi:10.1038/nrmicro2911 [PubMed: 23154262]
- Hawkins RA, Rank RG, Kelly KA (2000) Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo. *Infection and immunity* 68 (10):5587–5594 [PubMed: 10992458]
- Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J, Deeks SG (2010) HIV RNA level in early infection is predicted by viral load in the transmission source. *AIDS* 24 (7):941–945. doi:10.1097/QAD.0b013e328337b12e [PubMed: 20168202]
- Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Gunthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM (2012) Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. *PLoS Pathog* 8 (3):e1002529. doi:10.1371/journal.ppat.1002529 [PubMed: 22412369]
- Hladik F, McElrath MJ (2008) Setting the stage: host invasion by HIV. *Nat Rev Immunol* 8 (6):447–457. doi:nri2302 [pii] 10.1038/nri2302 [PubMed: 18469831]
- Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. *Immunity* 26 (2):257–270. doi:S1074-7613(07)00134-3 [pii] 10.1016/j.immuni.2007.01.007 [PubMed: 17306567]
- Hunter E (1997) Viral Entry and Receptors. In: Coffin JM, Hughes SH, Varmus HE (eds) *Retroviruses* Cold Spring Harbor (NY),
- Iglesias MC, Almeida JR, Fastenackels S, van Bockel DJ, Hashimoto M, Venturi V, Gostick E, Urrutia A, Wooldridge L, Clement M, Gras S, Wilmann PG, Autran B, Moris A, Rossjohn J, Davenport MP, Takiguchi M, Brander C, Douek DC, Kelleher AD, Price DA, Appay V (2011) Escape from highly effective public CD8+ T-cell clonotypes by HIV. *Blood* 118 (8):2138–2149. doi:10.1182/blood-2011-01-328781 [PubMed: 21734237]
- Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn CA, Collman RG (2009) Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. *J Virol* 83 (16):8208–8220. doi:JVI.00296-09 [pii] 10.1128/JVI.00296-09 [PubMed: 19515785]
- Iyer SS, Bibollet-Ruche F, Sherrill-Mix S, Learn GH, Plenderleith L, Smith AG, Barbian HJ, Russell RM, Gondim MV, Bahari CY, Shaw CM, Li Y, Decker T, Haynes BF, Shaw GM, Sharp PM, Borrow P, Hahn BH (2017) Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. *Proc Natl Acad Sci U S A* 114 (4):E590–E599. doi:10.1073/pnas.1620144114 [PubMed: 28069935]
- Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD (1999) Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. *J Exp Med* 189 (6):991–998 [PubMed: 10075982]

- Joseph SB, Swanstrom R, Kashuba AD, Cohen MS (2015) Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. *Nat Rev Microbiol* 13 (7):414–425. doi:10.1038/nrmicro3471 [PubMed: 26052661]
- Kamali A, Price MA, Lakhi S, Karita E, Inambao M, Sanders EJ, Anzala O, Latka MH, Bekker LG, Kaleebu P, Asiki G, Ssetaala A, Ruzagira E, Allen S, Farmer P, Hunter E, Mutua G, Makkan H, Tichacek A, Brill IK, Fast P, Stevens G, Chetty P, Amornkul PN, Gilmour J, 7 (2015) Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission. *PLoS One* 10 (1):e0116100. doi:10.1371/journal.pone.0116100 [PubMed: 25602351]
- Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL (1996) Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. *Nat Med* 2 (4): 405–411 [PubMed: 8597949]
- Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung'u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M, Goulder P (2009) Adaptation of HIV-1 to human leukocyte antigen class I. *Nature* 458 (7238): 641–645. doi:10.1038/nature07746 [PubMed: 19242411]
- Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A* 105 (21):7552–7557. doi:0802203105 [pii] 10.1073/pnas.0802203105 [PubMed: 18490657]
- Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y, Yeh WW, Letvin NL, Mascola JR, Nabel GJ, Haynes BF, Bhattacharya T, Perelson AS, Korber BT, Hahn BH, Shaw GM (2009) Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. *J Exp Med* 206 (5):1117–1134. doi:jem.20082831 [pii] 10.1084/jem.20082831 [PubMed: 19414559]
- Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. *Nat Med* 13 (1): 46–53. doi:nm1520 [pii] 10.1038/nm1520 [PubMed: 17173051]
- Kiwanuka N, Laeyendecker O, Quinn TC, Wawer MJ, Shepherd J, Robb M, Kigozi G, Kagaayi J, Serwadda D, Makumbi FE, Reynolds SJ, Gray RH (2009) HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. *AIDS* 23 (18): 2479–2484. doi:10.1097/QAD.0b013e328330cc08 [PubMed: 19841572]
- Klatt NR, Silvestri G, Hirsch V (2012) Nonpathogenic simian immunodeficiency virus infections. *Cold Spring Harb Perspect Med* 2 (1):a007153. doi:10.1101/cshperspect.a007153 [PubMed: 22315718]
- Kmieciak D, Iyer SS, Sturzel CM, Sauter D, Hahn BH, Kirchhoff F (2016) Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance. *mBio* 7 (4). doi:10.1128/mBio.00934-16
- Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol* 68 (7):4650–4655 [PubMed: 8207839]
- Lee HY, Giorgi EE, Keele BF, Gaschen B, Athreya GS, Salazar-Gonzalez JF, Pham KT, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Hahn BH, Shaw GM, Korber BT, Bhattacharya T, Perelson AS (2009) Modeling sequence evolution in acute HIV-1 infection. *J Theor Biol* 261 (2): 341–360. doi:S0022-5193(09)00350-6 [pii] 10.1016/j.jtbi.2009.07.038 [PubMed: 19660475]

- Leslie AJ, Pfafferoth KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD, Goulder PJ (2004) HIV evolution: CTL escape mutation and reversion after transmission. *Nat Med* 10 (3):282–289. doi:10.1038/nm992nm992 [pii] [PubMed: 14770175]
- Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT (2009) Glycerol monolaurate prevents mucosal SIV transmission. *Nature* 458 (7241):1034–1038. doi:nature07831 [pii] 10.1038/nature07831 [PubMed: 19262509]
- Liu A, Yang Y, Liu L, Meng Z, Li L, Qiu C, Xu J, Zhang X (2014) Differential compartmentalization of HIV-targeting immune cells in inner and outer foreskin tissue. *PLoS One* 9 (1):e85176. doi: 10.1371/journal.pone.0085176 [PubMed: 24454812]
- Liu J, Keele BF, Li H, Keating S, Norris PJ, Carville A, Mansfield KG, Tomaras GD, Haynes BF, Kolodkin-Gal D, Letvin NL, Hahn BH, Shaw GM, Barouch DH (2010) Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. *J Virol* 84 (19):10406–10412. doi:10.1128/JVI.01155-10 [PubMed: 20686016]
- Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. *Cell* 86 (3):367–377 [PubMed: 8756719]
- Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J (2002) HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. *AIDS Res Hum Retroviruses* 18 (8):567–576. doi: 10.1089/088922202753747914 [PubMed: 12036486]
- Ma ZM, Stone M, Piatak M, Jr., Schweighardt B, Haigwood NL, Montefiori D, Lifson JD, Busch MP, Miller CJ (2009) High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. *J Virol* 83 (7):3288–3297. doi:JVI.02423-08 [pii] 10.1128/JVI.02423-08 [PubMed: 19129448]
- Margolis L, Shattock R (2006) Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved? *Nat Rev Microbiol* 4 (4):312–317. doi:10.1038/nrmicro1387 [PubMed: 16541138]
- Martinez-Picado J, Prado JG, Fry EE, Pfafferoth K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P (2006) Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. *J Virol* 80 (7):3617–3623. doi:10.1128/JVI.80.7.3617-3623.2006 [PubMed: 16537629]
- Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA (1998) Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. *J Virol* 72 (1):164–169 [PubMed: 9420212]
- McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, Buchbinder S, Carrington MN, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, Poli G, Sandhu MS, Schuitemaker H, Shea PR, Theodorou I, Walker BD, Weintrob AC, Winkler CA, Wolinsky SM, Raychaudhuri S, Goldstein DB, Telenti A, de Bakker PI, Zagury JF, Fellay J (2015) Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. *Proc Natl Acad Sci U S A* 112 (47):14658–14663. doi:10.1073/pnas.1514867112 [PubMed: 26553974]
- Mellors JW, Kingsley LA, Rinaldo CR, Jr., Todd JA, Hoo BS, Kokka RP, Gupta P (1995) Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med* 122 (8):573–579 [PubMed: 7887550]
- Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW (1997) The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. *Nat Med* 3 (3):338–340 [PubMed: 9055864]

- Miller WC, Rosenberg NE, Rutstein SE, Powers KA (2010) Role of acute and early HIV infection in the sexual transmission of HIV. *Curr Opin HIV AIDS* 5 (4):277–282. doi:10.1097/COH.0b013e32833a0d3a01222929-201007000-00004 [pii] [PubMed: 20543601]
- Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, Trocha A, Block BL, Schneidewind A, Allen TM, Heckerman D, Walker BD (2009) HLA-associated alterations in replication capacity of chimeric NL4–3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. *J Virol* 83 (1):140–149. doi:10.1128/JVI.01471-08 [PubMed: 18971283]
- Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, Kaufmann DE, Trocha A, Block BL, Daar ES, Connick E, Jessen H, Kelleher AD, Rosenberg E, Markowitz M, Schafer K, Vaida F, Iwamoto A, Little S, Walker BD (2010) Impaired replication capacity of acute/early viruses in persons who become HIV controllers. *J Virol* 84 (15):7581–7591. doi:10.1128/JVI.00286-10 [PubMed: 20504921]
- Monaco DC, Dilemnia DA, Fiore-Gartland A, Yu T, Prince JL, Dennis KK, Qin K, Schaefer M, Claiborne DT, Kilembe W, Tang J, Price MA, Farmer P, Gilmour J, Bansal A, Allen S, Goepfert P, Hunter E (2016) Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression. *J Exp Med* 213 (10):2049–2063. doi:10.1084/jem.20151984 [PubMed: 27551154]
- Nawaz F, Cicala C, Van Ryk D, Block KE, Jelacic K, McNally JP, Ogundare O, Pascuccio M, Patel N, Wei D, Fauci AS, Arthos J (2011) The genotype of early-transmitting HIV gp120s promotes alphabeta-reactivity, revealing alphabetaCD4+ T cells as key targets in mucosal transmission. *PLoS pathogens* 7 (2):e1001301. doi:10.1371/journal.ppat.1001301 [PubMed: 21383973]
- Oberle CS, Joos B, Rusert P, Campbell NK, Beauparlant D, Kuster H, Weber J, Schenkel CD, Scherrer AU, Magnus C, Kouyos R, Rieder P, Niederost B, Braun DL, Pavlovic J, Boni J, Yerly S, Klimkait T, Aubert V, Trkola A, Metzner KJ, Gunthard HF, Swiss HIVCS (2016) Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. *Retrovirology* 13 (1):62. doi:10.1186/s12977-016-0299-0 [PubMed: 27595568]
- Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC (2012) Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. *J Virol* 86 (5):2715–2728. doi:10.1128/JVI.06157-11 [PubMed: 22190722]
- Paiardini M, Pandrea I, Apetrei C, Silvestri G (2009) Lessons learned from the natural hosts of HIV-related viruses. *Annu Rev Med* 60:485–495. doi:10.1146/annurev.med.60.041807.123753 [PubMed: 19630581]
- Pandrea I, Apetrei C (2010) Where the wild things are: pathogenesis of SIV infection in African nonhuman primate hosts. *Curr HIV/AIDS Rep* 7 (1):28–36. doi:10.1007/s11904-009-0034-8 [PubMed: 20425055]
- Pandrea I, Onanga R, Souquiere S, Mouinga-Ondeme A, Bourry O, Makuwa M, Rouquet P, Silvestri G, Simon F, Roques P, Apetrei C (2008) Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. *J Virol* 82 (11):5501–5509. doi:10.1128/JVI.02555-07 [PubMed: 18385229]
- Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Jr., Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH (2013) Phenotypic properties of transmitted founder HIV-1. *Proc Natl Acad Sci U S A* 110 (17):6626–6633. doi:10.1073/pnas.1304288110 [PubMed: 23542380]
- Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW (2012) Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. *PLoS Pathog* 8 (5):e1002686. doi:10.1371/journal.ppat.1002686 [PubMed: 22693444]

- Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, Powers KA, Galvin S, Chilongozi D, Gama S, Price MA, Fiscus SA, Cohen MS (2007) Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. *AIDS* 21 (13):1723–1730. doi:10.1097/QAD.0b013e3281532c82 [PubMed: 17690570]
- Powers KA, Poole C, Pettifor AE, Cohen MS (2008) Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. *The Lancet infectious diseases* 8 (9):553–563. doi: 10.1016/S1473-3099(08)70156-7 [PubMed: 18684670]
- Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, Prentice HA, Yue L, Vishwanathan SA, Kilembe W, Goepfert P, Price MA, Gilmour J, Mulenga J, Farmer P, Derdeyn CA, Tang J, Heckerman D, Kaslow RA, Allen SA, Hunter E (2012) Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. *PLoS Pathog* 8 (11):e1003041. doi:10.1371/journal.ppat.1003041 [PubMed: 23209412]
- Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N Engl J Med* 342 (13):921–929. doi:10.1056/NEJM200003303421303 [PubMed: 10738050]
- Redd AD, Collinson-Streng AN, Chatziandreou N, Mullis CE, Laeyendecker O, Martens C, Ricklefs S, Kiwanuka N, Nyein PH, Lutalo T, Grabowski MK, Kong X, Manucci J, Sewankambo N, Wawer MJ, Gray RH, Porcella SF, Fauci AS, Sagar M, Serwadda D, Quinn TC (2012) Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. *J Infect Dis* 206 (9):1433–1442. doi:10.1093/infdis/jis503 [PubMed: 22997233]
- Regoes RR, Bonhoeffer S (2005) The HIV coreceptor switch: a population dynamical perspective. *Trends Microbiol* 13 (6):269–277. doi:10.1016/j.tim.2005.04.005 [PubMed: 15936659]
- Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, Masson L, Werner L, Garrett N, Passmore JA, Karim QA, Karim SS, Williamson C, Moore PL, Morris L (2015) South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on alpha4beta7 for replication. *Retrovirology* 12:54. doi:10.1186/s12977-015-0183-3 [PubMed: 26105197]
- Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J, investigators St (2015) Structured observations reveal slow HIV-1 CTL escape. *PLoS genetics* 11 (2):e1004914. doi:10.1371/journal.pgen.1004914 [PubMed: 25642847]
- Sagar M, Laeyendecker O, Lee S, Gamiel J, Wawer MJ, Gray RH, Serwadda D, Sewankambo NK, Shepherd JC, Toma J, Huang W, Quinn TC (2009) Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. *J Infect Dis* 199 (4):580–589. doi: 10.1086/596557 [PubMed: 19143562]
- Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandalisa K, Ndinya-Achola JO, Kreiss JK, Overbaugh J (2004) Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. *AIDS* 18 (4):615–619. doi:00002030-200403050-00005 [pii] [PubMed: 15090766]
- Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J, Anderson JA, Swanstrom R, Haynes BF, Athreya GS, Korber BT, Sharp PM, Shaw GM, Hahn BH (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. *J Virol* 82 (8):3952–3970. doi:JVI.02660-07 [pii] 10.1128/JVI.02660-07 [PubMed: 18256145]
- Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *J Exp Med* 206 (6):1273–1289. doi:jem.20090378 [pii] 10.1084/jem.20090378 [PubMed: 19487424]
- Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cogniaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana

- S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature* 382 (6593):722–725. doi:10.1038/382722a0 [PubMed: 8751444]
- Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB, Jr., Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC (2014) Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. *Nature* 511 (7511):601–605. doi:10.1038/nature13554 [PubMed: 25043006]
- Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. *Science* 283 (5403):857–860 [PubMed: 9933172]
- Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM, Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM (2007) Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. *J Virol* 81 (22):12382–12393. doi:10.1128/JVI.01543-07 [PubMed: 17804494]
- Schneidewind A, Brumme ZL, Brumme CJ, Power KA, Reyor LL, O'Sullivan K, Gladden A, Hempel U, Kuntzen T, Wang YE, Oniangue-Ndza C, Jessen H, Markowitz M, Rosenberg ES, Sekaly RP, Kelleher AD, Walker BD, Allen TM (2009) Transmission and long-term stability of compensated CD8 escape mutations. *J Virol* 83 (8):3993–3997. doi:10.1128/JVI.01108-08 [PubMed: 19091871]
- Selhorst P, Combrinck C, Ndabambi N, Ismail SD, Abrahams MR, Lacerda M, Samsunder N, Garrett N, Abdool Karim Q, Abdool Karim SS, Williamson C (2017a) Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression. *J Virol* 91 (8). doi:10.1128/JVI.01806-16
- Selhorst P, Masson L, Ismail SD, Samsunder N, Garrett N, Mansoor LE, Abdool Karim Q, Abdool Karim SS, Passmore JS, Williamson C (2017b) Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. *Clin Infect Dis* 64 (1):79–82. doi:10.1093/cid/ciw663 [PubMed: 27694480]
- Shaw GM, Hunter E (2012) HIV transmission. *Cold Spring Harb Perspect Med* 2 (11). doi:10.1101/cshperspect.a006965
- Stieh DJ, Maric D, Kelley ZL, Anderson MR, Hattaway HZ, Beilfuss BA, Rothwangl KB, Veazey RS, Hope TJ (2014) Vaginal challenge with an SIV-based dual reporter system reveals that infection can occur throughout the upper and lower female reproductive tract. *PLoS Pathog* 10 (10):e1004440. doi:10.1371/journal.ppat.1004440 [PubMed: 25299616]
- Stieh DJ, Matias E, Xu H, Fought AJ, Blanchard JL, Marx PA, Veazey RS, Hope TJ (2016) Th17 Cells Are Preferentially Infected Very Early after Vaginal Transmission of SIV in Macaques. *Cell host & microbe* 19 (4):529–540. doi:10.1016/j.chom.2016.03.005 [PubMed: 27078070]
- Trask SA, Derdeyn CA, Fideli U, Chen Y, Meleth S, Kasolo F, Musonda R, Hunter E, Gao F, Allen S, Hahn BH (2002) Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. *J Virol* 76 (1):397–405 [PubMed: 11739704]
- UNAIDS (2016) Global AIDS
- Veazey RS, Pilch-Cooper HA, Hope TJ, Alter G, Carias AM, Sips M, Wang X, Rodriguez B, Sieg SF, Reich A, Wilkinson P, Cameron MJ, Lederman MM (2016) Prevention of SHIV transmission by topical IFN-beta treatment. *Mucosal Immunol* 9 (6):1528–1536. doi:10.1038/mi.2015.146 [PubMed: 26838048]
- Walker BD, Yu XG (2013) Unravelling the mechanisms of durable control of HIV-1. *Nat Rev Immunol* 13 (7):487–498. doi:10.1038/nri3478 [PubMed: 23797064]
- Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC (2005) Rates

- of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. *J Infect Dis* 191 (9):1403–1409. doi:JID33445 [pii] 10.1086/429411 [PubMed: 15809897]
- Wilén CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW (2011) Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. *J Virol* 85 (17):8514–8527. doi:10.1128/JVI.00736-11 [PubMed: 21715507]
- Wilén CB, Tilton JC, Doms RW (2012) HIV: Cell Binding and Entry. *Cold Spring Harbor Perspectives in Medicine* 2 (8):a006866. doi:10.1101/cshperspect.a006866 [PubMed: 22908191]
- Wolfs TF, Zwart G, Bakker M, Goudsmit J (1992) HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. *Virology* 189 (1):103–110 [PubMed: 1376536]
- Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL (1992) Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. *Science* 255 (5048):1134–1137 [PubMed: 1546316]
- Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, Wang B, Losina E, Miura T, Chonco F, van der Stok M, Mncube Z, Bishop K, Goulder PJ, Walker BD, Brockman MA, Ndung'u T (2010) Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. *J Virol* 84 (20):10820–10831. doi:10.1128/JVI.01084-10 [PubMed: 20702636]
- Wright JK, Novitsky V, Brockman MA, Brumme ZL, Carlson JM, Heckerman D, Wang B, Losina E, Leshwedi M, van der Stok M, Maphumulo L, Mkhwanazi N, Chonco F, Goulder PJ, Essex M, Walker BD, Ndung'u T (2011) Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. *J Virol* 85 (8):3996–4006. doi:10.1128/JVI.02520-10 [PubMed: 21289112]
- Yokomaku Y, Miura H, Tomiyama H, Kawana-Tachikawa A, Takiguchi M, Kojima A, Nagai Y, Iwamoto A, Matsuda Z, Ariyoshi K (2004) Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. *J Virol* 78 (3):1324–1332 [PubMed: 14722287]
- Yue L, Pfaffertott KJ, Baalwa J, Conrod K, Dong CC, Chui C, Rong R, Claiborne DT, Prince JL, Tang J, Ribeiro RM, Cormier E, Hahn BH, Perelson AS, Shaw GM, Karita E, Gilmour J, Goepfert P, Derdeyn CA, Allen SA, Borrow P, Hunter E (2015) Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. *PLoS Pathog* 11 (1):e1004565. doi:10.1371/journal.ppat.1004565 [PubMed: 25569444]
- Yue L, Prentice HA, Farmer P, Song W, He D, Lakhi S, Goepfert P, Gilmour J, Allen S, Tang J, Kaslow RA, Hunter E (2013) Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection. *J Virol* 87 (2):708–715. doi:10.1128/JVI.02118-12 [PubMed: 23115285]
- Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P (1993) Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. *J Virol* 67 (6):3345–3356 [PubMed: 8497055]
- Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD (1993) Genotypic and phenotypic characterization of HIV-1 patients with primary infection. *Science* 261 (5125):1179–1181 [PubMed: 8356453]
- Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD (1996) Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. *J Virol* 70 (5):3098–3107 [PubMed: 8627789]
- Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, Cohen O, Rubbert A, Lam G, Vaccarezza M, Kennedy PE, Kumaraswami V, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB, Murphy PM (1997) Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. *Mol Med* 3 (1):23–36 [PubMed: 9132277]

Figure 1. Potential barriers to HIV transmission across the genital mucosa.

During transmission, the virus encounters a number of barriers to infection including mucous and epithelial layers that can block access to target cells. However, viruses can penetrate host defenses through temporary breaks in the epithelium or dendritic cell sampling the mucosal environment. The entering viruses must interact with susceptible $CD4^+ CCR5^+$ T cells to propagate since entry into non-permissive resting $CD4^+$ T cells will result in non-productive infection. Similarly, if the RC of the virus is unable to sustain a spreading infection ($R_0 < 1.0$), even infection of susceptible cells will not result in dissemination. It is likely that viruses with a replicative advantage will outcompete those that replicate less efficiently. Initial target cells are most likely susceptible $CD4^+ CCR5^+$ T cells, a majority of which may be of a Th17 lineage, but infection of macrophages and dendritic cells has also been reported. These cells can replicate virus locally or traffic to local secondary lymphoid structures, though virus could also diffuse there directly. Once virus reaches local lymph nodes and disseminates throughout the body, specifically to the gut mucosa, viral load increases exponentially in the blood. Approximately 70–80% of mucosal infections are established by single variants. Adapted from Ende and Hunter (Ende et al. 2017)

Figure. 2. Selection bias in heterosexual HIV-1 transmission.

The odds that the transmitting partner's amino acid will be transmitted to the recipient is a function of the relative frequency of the amino acid in the donor virus quasi-species. The plot shows the empirical transmission probability (odds on a log10 scale) of a variant as a function of the relative *in vivo* frequency of the variant in the donor quasi-species, with a near 1-to-1 mapping for variants that match cohort consensus. In contrast, polymorphisms are uniformly less likely to be transmitted. Adapted from (Carlson et al. 2014)

Figure 3. The balance between transmitted viral characteristics and early CTL immune responses determines disease progression.

High pre-adaptation and RC of the transmitted virus will tip the scale in favor of rapid disease progression. Pre-adaptation leads to impaired cytotoxic immune responses since the transmitted escape mutations prevent HLA molecules from presenting HIV epitopes (1) or lead to the presentation of epitopes that are poorly recognized by the TCR on the CTLs (2). High replication contributes with larger viral loads and proportions of infected cells, including the subsets associated with latency. On the other hand, large numbers of non-associated polymorphisms and strong, poly-functional cytotoxic immune responses tip the scale in favor of slow disease progression or control. These polymorphisms impair virus replication (3) but may as well negatively impact innate immune responses while the activity of strong, poly-functional CTLs contributes to reducing viral load (4).